Comments
Loading...
NovoCure Stock Guidance | NASDAQ:NVCR | Benzinga
NovoCure issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01/13/2025 | NVCR | NovoCure | Q4 | 2024 | — | — | — | $161.00M | $161.00M | $153.05M | Get Alert |
| 01/13/2025 | NVCR | NovoCure | FY | 2024 | — | — | — | $605.00M | $605.00M | $596.95M | Get Alert |
| 01/08/2024 | NVCR | NovoCure | FY | 2023 | — | — | — | $509.30M | $509.30M | $505.05M | Get Alert |
| 01/08/2024 | NVCR | NovoCure | Q4 | 2023 | — | — | — | $133.80M | $133.80M | $129.30M | Get Alert |
| 01/09/2023 | NVCR | NovoCure | FY | 2022 | — | — | — | $537.80M | $537.80M | $538.28M | Get Alert |
| 01/09/2023 | NVCR | NovoCure | Q4 | 2022 | — | — | — | $128.40M | $128.40M | $129.14M | Get Alert |
| 01/10/2022 | NVCR | NovoCure | FY | 2021 | — | — | — | $535.00M | $535.00M | $539.23M | Get Alert |
| 01/10/2022 | NVCR | NovoCure | Q4 | 2021 | — | — | — | $133.20M | $133.20M | $137.36M | Get Alert |
| 01/11/2021 | NVCR | NovoCure | Q4 | 2020 | — | — | — | $144.00M | $144.00M | $133.26M | Get Alert |
| 01/11/2021 | NVCR | NovoCure | FY | 2020 | — | — | — | $494.40M | $494.40M | $482.29M | Get Alert |
FAQ
What is the most recent guidance for NovoCure (NVCR)?
There have been no specific sales or earnings guidance reported for NovoCure in recent months.
Browse guidance and forecast on all stocks.